Our research projects
Find out more about the research projects you're helping us to fund. Together we can beat blood cancer.
Refine results
Finding new and better ways to treat leukaemia in babies
Some childhood leukaemias are caused by changes in a specific gene and are hard to treat, often returning after treatment. Dr Tom Milne’s research aims to develop new ways to treat leukaemia in babies.
Finding new ways to treat MPN
In this blood cancer research project, Dr Mishto wants to understand whether we might be able to harness our immune system to treat Myeloproliferative neoplasm (MPN).
Understanding whether we can prevent acute myeloid leukaemia
Find out more about Professor George Vassiliou's study into preventing people from developing acute myeloid leukaemia (AML), by seeing if DNMT3A is responsible for cells becoming ‘pre-leukaemic'.
Studying how the immune system behaves in myeloma
tba
Improving outcomes for people with MDS/MPN Overlap Syndromes
Discover Dr Daniel Wiseman's research into a new drug called ASTX727, to see if it can extend and improve the lives of people with MDS/MPN Overlap Syndromes.
The STELLAR trial: Finding new treatments for Richter’s syndrome
Richter’s syndrome is a complication of chronic lymphocytic leukaemia. Blood Cancer UK researchers will add a drug to treatment to see if this improves outcome.
EuroNet-PHL-C2 trial
Researchers are exploring whether tailored chemotherapy can reduce the need for radiotherapy in children and young people.
UKALL 2011
Discover Professor Pamela Kearns's UKALL 2011 trial that looks at treatment for children who have acute lymphoblastic leukaemia (ALL) or a type of non-Hodgkin lymphoma (NHL) called lymphoblastic lymphoma (LBL).
Repurposing drugs to treat acute myeloid leukaemia
Researchers are looking at whether existing drugs for solid tumours can treat AML. This could provide a new option for people with the disease.
Attacking the roots of acute myeloid leukaemia (AML)
Professor Göttgens’ team is analysing thousands of genes in single cells to identify those that drive pre‑leukaemia and test whether disrupting them can prevent AML from developing.
Understanding how acute myeloid leukaemia (AML) can go undetected by the immune system
Dr Lappin wants to understand how cancer cells can avoid detection by the immune system so she can find ways to help it to better target the cancer cells.
Understanding why people with acute myeloid leukaemia (AML) don’t always respond to treatment
Many people with acute myeloid leukaemia (AML) see their cancer come back. Dr Singh is studying a group of proteins to understand more about why drugs stop working.
Using the immune system to develop a new treatment for non-Hodgkin lymphoma (NHL)
Dr Blunt and team are looking for new ways to treat people with NHL using immunotherapy that activates the immune system to attack lymphoma cells.
Understanding how B-cell acute lymphoblastic leukaemia (B-ALL) spreads to the brain
B-cell acute lymphoblastic leukaemia (B-ALL) can spread to the brain and spinal cord, making it harder to treat in children. Dr Duguid will study brain tissue to find better treatments.
Finding new ways to stop leukaemia and lymphoma growing
Dr Feldhahn and team want to create new ways to study 'enhancers' so they can understand which ones are helping blood cancers to grow.
Mapping gene changes in ALL
A change in the BCR‑ABL gene can trigger acute lymphoblastic leukaemia (ALL). Dr Niklas Feldahn's research is uncovering what drives this process.
Understanding more the use of CT scans for children with blood cancer
Dr McNally’s research is exploring patterns in data to try to understand any potential risk of CT scans to help doctors to personalise treatment to each child based on their individual risk level.
Understanding the role of genes in how ALL develops in children
Dr Wright and team want to understand more about graft verses leukaemic (GVL) effect and graft-versus-host disease (GVHD) after a bone marrow transplant.
Finding new ways to target blood cancer with less side effects
Dr Mihkel Örd is studying molecules that block a key protein used by blood cancers, with the aim of developing better treatments with fewer side effects.
Identifying the tiny cells that causes AML to evade detection and survive
Professor Tonks plans to investigate a new method that could help ensure all AML cancer cells are destroyed so the cancer is unable to come back.
Understanding how AML cancer cells deal with stress
Dr Papamichos and his team are researching how AML cancer cells deal with stress so they can find ways to stop these cancer cells dividing and multiplying out of control.
Keep in touch with us
Get the latest news from Blood Cancer UK directly to your inbox
We will keep you updated about our work and the ways you can help, including campaigns and events. We promise to respect your privacy and we will never sell or swap your details.